Download PDFPDF

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Inhaled corticosteroids and mortality in COPD

    Dear Editor,

    We read with interest the recent paper by Sin and colleagues (1) which, we believe, raises more questions that it answers.

    A major concern is the fact that ascertainment of mortality was incomplete for a significant proportion of patients (973/5086), corresponding to 19% of the total (not the reported 12%), who did withdraw prematurely from the study. This loss to follow up was more likely...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Inhaled corticosteroids and COPD mortality: are we there yet?

    Dear Editor,

    Inhaled corticosteroids have for some time been seeking a broader indication in COPD. The recent meta-analysis by Sin et al.[1] suggesting protection against all-cause mortality is therefore of some interest. Although not universally confirmed[2,3], this tantalising concept is being prospectively evaluated in a 3 year study of high dose inhaled corticosteroids (Flixotide 500mcg bid, alone or in combina...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Inhaled steroids Protect Heart in COPD Patients

    Dear Editor

    Chronic obstructive pulmonary disease and other disorders, associated with reduced lung function, are strong risk factors for cardiovascular events, independent of smoking. In general, for every 10% decrease in FEV1, all-cause mortality increases by 14%, cardiovascular mortality increases by 28%1. Patients with chronic obstructive pulmonary disease (COPD) are predisposed to atherosclerosis and coronary...

    Show More
    Conflict of Interest:
    None declared.